Scholars Central

Conference abstract

Vaccine adjuvants; the good, the bad and the ugly

Authors: Nikolai Petrovsky

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

H ighly purified antigens suffer from poor immunogenicity. Current paradigms to address this problem focus onuse ofpotent innate immune activators as adjuvants, thereby mimicking natural infection. Unfortunately using this approach adjuvant immunogenicity and reactogenicity are largely inseparable. This talk will address the question of whether pro-inflammatory danger signals are really needed to make modern vaccines effective. Using examples of vaccines against influenza, West Nile virus, Japanese encephalitis virus and other important biodefense pathogens, data will be provided to show that bigger is not always better when it comes to vaccine adjuvants. Novel polysaccharide adjuvants such as delta inulin (Advax?) with more subtle immune effects surprisingly provide the best long-term immune memory responses and vaccine protection in the absence of generation of danger signals

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Nikolai Petrovsky”